# LAP07

Source: https://onco.cc/trials/lap07/  
OnCo record `lap07` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

LAP07 tested whether adding radiotherapy after four months of chemotherapy helps people whose pancreatic cancer has not spread but cannot be removed; it did not lengthen life, although it did keep the tumour in check locally for longer, and adding erlotinib to gemcitabine did not help either.

## Summary

LAP07 was an international open-label phase 3 trial run by GERCOR in 449 patients with locally advanced pancreatic cancer. Patients were first randomised to gemcitabine or gemcitabine with erlotinib for four months; the 269 whose disease was controlled were then randomised to capecitabine-based chemoradiotherapy or two more months of the same chemotherapy. The primary endpoint was overall survival.

The trial stopped for futility at the interim analysis: median overall survival was 16.5 months with chemotherapy and 15.2 months with chemoradiotherapy (hazard ratio 1.03), and 13.6 months with gemcitabine against 11.9 months with gemcitabine plus erlotinib (hazard ratio 1.19). Chemoradiotherapy did reduce local progression (32 against 46 percent) without more grade 3 to 4 toxicity except nausea. The corpus's locally advanced pancreatic cancer page cites LAP07 for better local control without longer survival.

## Fields

- Kind: Trial
- Status: negative
- Last checked: 2026-09-22
- Also known as: LAP 07; GERCOR LAP07
- Tags: soc-trials
- Registry id: NCT00634725
- Phase: 3
- Setting: Locally advanced unresectable pancreatic cancer: a first randomisation to four months of gemcitabine with or without erlotinib, then for patients without progression a second randomisation to capecitabine-based chemoradiotherapy (54 Gy) or two further months of chemotherapy
- Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
- Enrolled: 449
- Result: Median overall survival 15.2 months with chemoradiotherapy against 16.5 months with chemotherapy alone (hazard ratio 1.03, p 0.83); local progression 32 against 46 percent; erlotinib added nothing (13.6 against 11.9 months, hazard ratio 1.19).
- Outcomes: Overall survival from first randomisation, chemoradiotherapy against chemotherapy (second randomisation): Capecitabine-based chemoradiotherapy after 4 months of chemotherapy 15.2 months vs Two further months of chemotherapy 16.5 months, HR 1.03; Overall survival, gemcitabine against gemcitabine plus erlotinib (first randomisation): Gemcitabine 13.6 months vs Gemcitabine + erlotinib 11.9 months, HR 1.19; Local progression: Capecitabine-based chemoradiotherapy 32% vs Chemotherapy alone 46%

## Sources

- ClinicalTrials.gov NCT00634725: https://clinicaltrials.gov/study/NCT00634725

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Erlotinib](https://onco.cc/drugs/erlotinib/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/)
- key papers: [LAP07: chemoradiotherapy versus chemotherapy after four months of gemcitabine in locally advanced pancreatic cancer](https://onco.cc/key-papers/paper-lap07-chemoradiotherapy-locally-advanced-pancreatic-hammel-jama-2016/)

---
JSON: https://onco.cc/api/v1/entities/lap07.json